SLPI deficiency alters airway protease activity and induces cell recruitment in a model of muco-obstructive lung disease
暂无分享,去创建一个
S. Weldon | Ryan Brown | C. Houston | C. Dougan | R. Delaney | Marcus A. Mall | C. Taggart | Peter Ferris | Aoife Rodgers | Damian G. Downey | Marcus A. Mall | Bronwen Connolly | Donna M Small
[1] G. Einarsson,et al. Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations , 2023, European Respiratory Journal.
[2] Wells Jn,et al. Protease-armed, Pathogenic Extracellular Vesicles Link Smoking and COPD. , 2023, American journal of respiratory and critical care medicine.
[3] P. Moynagh,et al. Secretory Leucoprotease Inhibitor (SLPI) Promotes Survival during Acute Pseudomonas aeruginosa Infection by Suppression of Inflammation Rather Than Microbial Killing , 2022, Biomolecules.
[4] A. Gaggar,et al. An in vivo model for extracellular vesicle–induced emphysema , 2022, JCI insight.
[5] J. Elborn,et al. Therapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult βENaC-Tg Mice , 2021, Mediators of inflammation.
[6] F. Blasi,et al. Antimicrobial peptides, disease severity and exacerbations in bronchiectasis , 2019, Thorax.
[7] K. Borensztajn,et al. Targeting of cathepsin S reduces cystic fibrosis-like lung disease , 2019, European Respiratory Journal.
[8] A. Gaggar,et al. Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung , 2019, Cell.
[9] R. Snelgrove,et al. The multifaceted roles of the matrikine Pro-Gly-Pro in pulmonary health and disease , 2018, European Respiratory Review.
[10] F. Herth,et al. Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis , 2018, European Respiratory Journal.
[11] P. Bakke,et al. Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease , 2017, European Respiratory Journal.
[12] K. Murzyn,et al. Secretory leukocyte protease inhibitor (SLPI), a multifunctional protein in the host defense response. , 2016, Cytokine & growth factor reviews.
[13] P. Fitzgerald,et al. Cleaved SLPI as a marker for exacerbation in cystic fibrosis , 2015 .
[14] M. Cosio,et al. Destructive index: a measurement of lung parenchymal destruction in smokers. , 2015, The American review of respiratory disease.
[15] K. Ling,et al. Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis , 2015, European Respiratory Journal.
[16] O. Sommerburg,et al. Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema. , 2014, American journal of respiratory cell and molecular biology.
[17] C. Schultz,et al. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. , 2014, American journal of respiratory and critical care medicine.
[18] S. Safe,et al. Investigation of macrophage polarization using bone marrow derived macrophages. , 2013, Journal of visualized experiments : JoVE.
[19] C. Schultz,et al. CFTR Regulates Early Pathogenesis of Chronic Obstructive Lung Disease in βENaC-Overexpressing Mice , 2012, PloS one.
[20] S. Randell,et al. Genetically determined heterogeneity of lung disease in a mouse model of airway mucus obstruction. , 2012, Physiological genomics.
[21] J. Clancy,et al. Human Neutrophil Elastase-Mediated Cleavage Sites of MMP-9 and TIMP-1: Implications to Cystic Fibrosis Proteolytic Dysfunction , 2010, Molecular medicine.
[22] Paul McNally,et al. Decreased Levels of Secretory Leucoprotease Inhibitor in the Pseudomonas-Infected Cystic Fibrosis Lung Are Due to Neutrophil Elastase Degradation1 , 2009, The Journal of Immunology.
[23] J. Clancy,et al. A Novel Proteolytic Cascade Generates an Extracellular Matrix-Derived Chemoattractant in Chronic Neutrophilic Inflammation12 , 2008, The Journal of Immunology.
[24] A. Livraghi,et al. Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing mice. , 2008, American journal of respiratory and critical care medicine.
[25] S. Akira,et al. Potent Antimycobacterial Activity of Mouse Secretory Leukocyte Protease Inhibitor1 , 2008, The Journal of Immunology.
[26] N. McElvaney,et al. Secretory Leucocyte Protease Inhibitor Inhibits Interferon-γ-induced Cathepsin S Expression* , 2007, Journal of Biological Chemistry.
[27] E. Piitulainen,et al. Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe α1-antitrypsin deficiency , 2007, BMC pulmonary medicine.
[28] N. McElvaney,et al. Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding , 2005, The Journal of experimental medicine.
[29] Richard C Boucher,et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice , 2004, Nature Medicine.
[30] R. Stockley,et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD , 2001, Thorax.
[31] G. Steffens,et al. Antibacterial activity of antileukoprotease , 1996, Infection and immunity.
[32] Y. Okada,et al. Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 (‘gelatinase’) by human neutrophil elastase and cathepsin G , 1989, FEBS letters.
[33] K. Ohlsson,et al. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[34] W. Thurlbeck. Internal surface area and other measurements in emphysema , 1967, Thorax.